Opinion statement
The rapid increase in incidence of malignant melanoma has not been associated with better therapeutic options over the years. Single-agent chemotherapy or immunotherapy remain the treatments of choice when systemic therapy is offered. Dacarbazine (DTIC) is the chemotherapy of choice with a response rate of 16%. Other chemotherapies, including cisplatinum, paclitaxel, docetaxel and the DTIC analogue temozolomide, have shown activity in this disease. Based on their single-agent activity, several combination chemotherapies have been investigated with preliminary results that appeared promising. However, in randomized phase III trials the two most active chemotherapy combination regimens, cisplatin, vinblastine, and DTIC (CVD) and the Dartmouth regimen (DTIC, cisplatin, bischloroethylnitrosourea [BCNU], and tamoxifen), did not prove to be superior to single-agent DTIC for overall survival. Immunotherapy with either interleukin (IL)-2 or interferon (IFN) has demonstrated response rates of 10% to 15% in appropriately selected patients. In patients who achieve a complete response, responses can be of greater durability than those with chemotherapy. However, IL-2 and IFN administration are associated with multiple side effects, and only physicians experienced in the management of such therapies should administer them. The potential benefit of combining chemotherapy with immunotherapy has led to multiple phase II trials of biochemotherapy that appeared to be associated with higher response rates and longer median survivals. However, several phase III trials have been completed that have not consistently demonstrated an improvement in either response rates or overall survival, and these approaches to therapy cannot be routinely recommended outside the context of a clinical trial. The surgical resection of isolated metastatic disease has demonstrated an important palliative benefit in those patients who present with solitary single-organ disease with the exception of the liver. Radiation has an important role in the palliative management of brain metastasis and symptomatic bony metastasis. Both stereotactic radiosurgery and whole brain radiotherapy have been used alone and in combination to benefit patients in this troubling clinical circumstance. Isolated limb perfusion and a newer technique, isolated limb infusion have demonstrated high response rates for those uncommon patients who develop recurrent disease isolated to a limb. In our opinion, if complete metastasectomy is not feasible and in the absence of brain metastases, single-agent IL-2 is a good initial treatment choice in appropriately selected patients. Single-agent chemotherapy with DTIC is the treatment of choice for patients who are not candidates for IL-2. Adoptive immunotherapy combining nonmyeloablative chemotherapy with high-dose IL-2 is a potentially promising therapeutic strategy under investigation. Targeted therapy is also an area of promising development as single agents, in combination, and combined with chemotherapy. The latter will be the focus of at least one upcoming cooperative group phase III trial.
Similar content being viewed by others
References and Recommended Reading
Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8–29.
H Tsao, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998–1012. Excellent updated review.
Barth A, Wanek LA, Morton DL: Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 1995, 181:193–201.
Bajetta E, Del Vecchio M, Bernard-Marty C, et al.: Metastatic melanoma: chemotherapy. Semin Oncol 2002, 29:427–445.
Gogas H, Bafaloukos D, Bedikian AY: The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 2004, 14:415–420.
Bleehen NM, Newlands ES, Lee SM, et al.: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995, 130:910–913.
Middleton MR, Grob JJ, Aaronson N, et al.: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients With advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158.
Al Sarraf M, Fletcher W, Oishi N, et al.: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 1982, 66:31–35.
Glover D, Glick JH, Weiler C, Fox K, Guerry D: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987, 5:574–578.
Glover D, Ibrahim J, Kirkwood J, et al.: Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 2003, 13:619–626.
Lattanzi SC, Tosteson T, Chertoff J, et al.: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995, 5:365–369.
Chapman PB, Einhorn LH, Meyers ML, et al.: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745–2751. ortant randomized trial that disproved the superiority of the Dartmouth regimen
Legha SS, Ring S, Papadopoulos N, et al.: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989, 64:2024–2029.
Buzaid A, Legha S, Winn R, et al.: Cisplatin (C) vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology program (CCOP) trial. Proc Am Soc Clin Oncol 1993, 12:389.
Hwu WJ, Krown SE, Menell JH, et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003, 21:3351–3356.
Eton O, Legha SS, Bedikian AY, et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045–2052. domized controlled trial that showed the benefit of biochemotherapy over chemotherapy alone
Atkins MB, Lee S, Flaherty LE, et al.: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2, and IFN-α-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003, 22:708. ticenter randomized controlled trial revealing the lack of benefit of biochemotherapy.
Keilholz U, Punt CJ, Gore M, et al.: Dacarbazine, cisplatin and IFN-α-2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 2003, 22:708.
Atkins MB, Lotze MT, Dutcher JP, et al.: High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105–2116. ortant paper that supported the FDA approval for highdose IL-2 in metastatic melanoma.
Legha SS: The role of IFN-α in the treatment of metastatic melanoma. Semin Oncol 1997, 24:24–31. ntifies the benefit of IFN therapy in the treatment of melanoma.
Schwartzentruber DJ: Guidelines for the safe administration of high-dose interleukin-2. J Immuno 2001, 24:287–293.
Tarhini AA, Agarwala SS: Management of brain metastases in patients with melanoma. Curr Opin Oncol 2004, 16:161–166.
Lavine SD, Petrovich Z, Cohen-Gadol AA, et al.: Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery 1999, 44:59–64.
Brand CU, Ellwanger U, Stroebel W, et al.: Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997, 79:2345–2353.
Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer 2000, 89:1983–1991.
Ollila DW, Hsueh EC, Stern SL, Morton DL: Metastasectomy for recurrent stage IV melanoma. J Surg Oncol 1999, 71:209–213.
Alexander HR, Jr, Fraker DL, Bartlett DL: Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996, 12:416–428.
Thompson JF, Kam PC: Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004, 88:1–3.
Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004, 101(Suppl 2):14639–14645. Important study of a novel immunotherapy approach.
Flaherty KT, Brose M, Schuchter L, et al.: Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. Proceedings of ASCO annual meeting. New Orleans, LA; 2004.
Falkson CI, Ibrahim J, Kirkwood JM, et al.: Phase III trial of dacarbazine versus dacarbazine with interferon-α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-α-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998, 16:1743–1751. Important randomized controlled trial showing the lack of benefit of tamoxifen and IFN when added to chemotherapy in the therapy of metastatic melanoma.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Atallah, E., Flaherty, L. Treatment of metastatic malignant melanoma. Curr. Treat. Options in Oncol. 6, 185–193 (2005). https://doi.org/10.1007/s11864-005-0002-5
Issue Date:
DOI: https://doi.org/10.1007/s11864-005-0002-5